Results 1 to 10 of about 17,390 (157)

Pregnancy-Associated Atypical Hemolytic-Uremic Syndrome

American Journal of Perinatology Reports, 2016
Précis Introduction Early diagnosis of atypical uremic–hemolytic syndrome may be challenging during the puerperium period. Correct diagnosis and timely management are crucial to improve outcomes.
Antonio F. Saad, Jorge Roman, Aaron Wyble, Luis D. Pacheco   +3 more
doaj   +1 more source

Phenotypic manifestation of homozygous partial deletion of the chromosome 1 segment spanning CFHR3 region

Медицинская иммунология, 2020
This article presents two clinical cases of patients with a homozygous deletion of segment of chromosome 1, which covers regions of genes associated with complement factor H, in particular CFHR3.
I. A. Tuzankina, M. A. Bolkov, N. S. Zhuravleva, Yu. O. Vaseneva, Kh. Shinvari, O. V. Schipacheva   +5 more
doaj   +1 more source

Case Series of 3 Patients Diagnosed With Atypical Hemolytic Uremic Syndrome Successfully Treated With Steroids, Plasmapheresis, and Rituximab

Canadian Journal of Kidney Health and Disease, 2017
Rationale: Atypical hemolytic uremic syndrome, which has a high probability of chronic kidney disease, morbidity, and mortality, needs to be promptly recognized when patients present with microangiopathic hemolysis.
Jeffery M. Patterson, Lauren Bolster, Loree Larratt   +2 more
doaj   +1 more source

Síndrome hemolítico-urémico.

Acta Médica Portuguesa, 1999
The microangiopathic thrombotic syndromes--thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS)--are characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal dysfunction, fever and central nervous system ...
P A Rodrigues, J Machado, O Cardoso, J Cruz, F Carvalho, M da Costa, R Proença   +6 more
doaj   +1 more source

Successful use of eculizumab to treat atypical hemolytic uremic syndrome in patients with inflammatory bowel disease

Thrombosis Journal, 2019
Background Atypical hemolytic uremic syndrome is a rare group of disorders that have in common underlying complement amplifying conditions. These conditions can accelerate complement activation that results in a positive feedback cycle.
Ramy M. Hanna, Noah Merin, Richard M. Burwick, Lama Abdelnour, Umut Selamet, Beshoy Yanny, Patrick Bui, Mary Fouad, Ira Kurtz   +8 more
doaj   +1 more source

Pregnancy-associated hemolytic uremic syndrome

Saudi Journal of Kidney Diseases and Transplantation, 2020
Pregnancy-associated hemolytic uremic syndrome (P-aHUS) is not an uncommon condition. It is considered a medical emergency that is associated with a high risk of mortality and serious morbidity.
Sami Alobaidi, Ammar AlDabbagh, Amany Alamoudi, Murad Almowarey, Ahmed Akl   +4 more
doaj   +1 more source

Hemolytic uremic syndrome – emergency in an infant

Liječnički vjesnik, 2023
Hemolytic-uremic syndrome (HUS) is a serious condition characterized by hemolytic ane-mia, thrombocytopenia, and acute kidney failure. The most common cause of HUS in chil-dren is infection with Shiga toxin-producing E. coli (STEC).
Jana Jelčić, Ozana Jakšić, Maša Davidović   +2 more
doaj   +1 more source

Clostridium septicum Infection and Hemolytic Uremic Syndrome

Emerging Infectious Diseases, 1998
Five cases of Clostridium septicum infection secondary to Escherichia coli O157induced hemolytic uremic syndrome have been reported. We report on three cases (one of which is included in the above five) of dual Cl. septicum and E.
M. Barnham, N. Weightman
doaj   +1 more source

Atypical hemolytic uremic syndrome

Renal Replacement Therapy, 2017
Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure.
Yoko Yoshida, Hideki Kato, Masaomi Nangaku   +2 more
doaj   +1 more source

Primary Thrombotic Microangiopathy in Pediatric Patients

Global Pediatric Health
Background . Primary thrombotic microangiopathy includes hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli , atypical hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Methodology .
Andrés David Aranzazu Ceballos MD, Lina María Martínez Sánchez MSc, Ana Paulina Pamplona Sierra MD, Daniela Vergara Yánez MD, Liliana Franco Hincapié PhD, Richard Baquero Rodriguez MD   +5 more
doaj   +1 more source